SCHEMBL418400

SCHEMBL418400

COC(=O)c1cc(Cl)ccc1NC(=O)c1cccc(-c2ccccc2OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 6/20 0.60
KDM4E B2RXH2 4/20 0.54
HSD17B10 Q99714 2/20 0.54
MAPK1 P28482 1/20 0.54
KAT6A Q92794 1/20 0.53
ALDH1A1 P00352 4/20 0.53
GAA P10253 2/20 0.53
SMN1; SMN2 Q16637 4/20 0.52
MAPT P10636 2/20 0.52
GRM5 P41594 1/20 0.51
LMNA P02545 1/20 0.51
KMT2A Q03164 1/20 0.51
SIRT2 Q8IXJ6 1/20 0.51
HPGD P15428 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
AKR1C4 P17516 1/20 0.50
AKR1C3 P42330 1/20 0.50
AKR1C2 P52895 1/20 0.50
AKR1C1 Q04828 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417027 0.91 SERPINE1 (0.73) SERPINE1KDM4EKAT6AALDH1A1GAA
SCHEMBL420185 0.88 SERPINE1 (0.77) SERPINE1KDM4EHSD17B10MAPK1ALDH1A1
SCHEMBL419689 0.86 SERPINE1 (0.78) SERPINE1ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL6295715 0.83 KMT2A (0.58) KAT6AALDH1A1SMN1; SMN2GRM5LMNA
SCHEMBL421465 0.82 SERPINE1 (0.65) SERPINE1KDM4EALDH1A1GAAMAPT
SCHEMBL417914 0.81 SERPINE1 (0.64) SERPINE1MAPTAKR1C4AKR1C3AKR1C2
SCHEMBL418419 0.81 SERPINE1 (0.77) SERPINE1GAAMAPTLMNAKMT2A
SCHEMBL418470 0.81 SMN1; SMN2 (0.57) SERPINE1KDM4EHSD17B10ALDH1A1GAA
SCHEMBL418492 0.80 AKR1C4 (0.57) SERPINE1KDM4EHSD17B10MAPK1ALDH1A1
SCHEMBL420949 0.80 SERPINE1 (0.78) SERPINE1MAPK1ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885KDM4E 4490/4885HSD17B10 1809/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885KDM4E 4490/4885HSD17B10 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.